Product Pathways - Growth Factors/Cytokines
Mouse Interleukin-13 (mIL-13) #5242
|5242LC||25 µg (With Carrier)||---||In Stock||---|
|5242LF||25 µg (Carrier Free)||---||In Stock||---|
|5242SC||5 µg (With Carrier)||---||In Stock||---|
|5242SF||5 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant mouse IL-13 (mIL-13) Ser26-Phe131 (Accession #NP_032381) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant mIL-13 contains no "tags" and the nonglycosylated protein has a calculated MW of 11,677. DTT-reduced and non-reduced protein migrate as 12-20 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal SVSLP of recombinant mIL-13 was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-13. All lots are greater than 98% pure.
The bioactivity of recombinant mIL-13 was determined in a B9 cell proliferation assay. The ED50 of each lot is between 0.8 - 4 ng/ml.
The purity of recombinant mIL-13 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIL-13 and staining overnight with Coomassie Blue.
The proliferation of B9 cells treated with increasing concentrations of mIL-13 was assessed. After 48 hour treatment with mIL-13, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
Western blot analysis of extracts from TF-1 cells untreated or treated with mIL-13 for 10 minutes, using Phospho-Stat6 (Tyr641) (C11A12) Rabbit mAb Antibody #9364 (upper) and Stat6 Antibody #9362 (lower).
Less than 0.01 ng endotoxin/1μg mIL-13.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mIL-13. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-13 is produced by T cells and is important in the TH2 response. IL-13 targets include B cells, eosinophils, fibroblasts, mast cells and macrophages (1-3). IL-13 binds specifically to IL-13Rα1 that complexes with IL-4Rα to form the Type II IL-4R. Jak1 and Tyk2 are activated and signal through Stat3 and Stat6 (4). IL-13Rα2 is a different gene product, lacks the intracellular domain, does not complex with IL-4Rα and does not signal (1,4,5). The extracellular domain of IL-13Rα2 is often elevated in diseased states. IL-13 plays key roles in airway hyperresponsiveness (AHR) of allergic asthma (1,6,7) and modulates resistance to parasitic organisms (1).
- Wynn, T.A. (2003) Annu Rev Immunol 21, 425-56.
- Katz, Y. et al. (1995) Clin Exp Immunol 101, 150-6.
- McKenzie, A.N. et al. (1993) Proc Natl Acad Sci USA 90, 3735-9.
- Wills-Karp, M. and Finkelman, F.D. (2008) Sci Signal 1, pe55.
- Mentink-Kane, M.M. et al. (2004) Proc Natl Acad Sci U S A 101, 586-90.
- Wills-Karp, M. et al. (1998) Science 282, 2258-61.
- Nakajima, H. and Takatsu, K. (2007) Int Arch Allergy Immunol 142, 265-73.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.